Novo Nordisk, the maker of the popular weight-loss drug Wegovy, has raised its financial guidance for the full year following a strong second quarter. The Danish pharmaceutical company now expects its annual sales and operating profit to decline by up to 6% at constant exchange rates, an improvement from its previous forecast of a 4% to 12% decline.

This upward revision comes after the company reported a significant boost in its second-quarter results. Adjusted sales for the period rose 7% year-over-year, reaching 78.49 billion Danish kroner (approximately $12.08 billion). Adjusted operating profit also saw a healthy increase, growing 11% to 33.39 billion kroner.

The improved outlook reflects the continued demand for Novo Nordisk's products and its ability to navigate market challenges effectively. The company's performance in the second quarter provides a solid foundation for its revised financial projections.